Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
doi: 10.3389/fphys.2025.1734360 Received 28 October 2025 Revised 26 November 2025 Accepted 27 November 2025 Published 05 January 2026 Volume 16 - 2025 Edited by Sal A
All information provided pertains strictly to research observations and experimental analysis
Berberine's extensive drug interaction profile makes it unsuitable for many individuals on polypharmacy, particularly those taking anticoagulants (e.g., warfarin), immunosuppressants (e.g., ciclosporin, tacrolimus), or medications with narrow therapeutic indices
Statistical significance is calculated by one-way ANOVA followed by a correction for multiple comparisons as indicated in Section Materials and Methods. ANOVA, analysis of variance
Coverage depends on your insurance company, pharmacy benefits, diagnosis, BMI, medical necessity, and prior authorization requirements
Comparison with the Pocket Manual di Terapia confirms the robustness of this pharmacological class
US$ 23.94
US$ 24.45
US$ 24.72
US$ 29.25
